Headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2581765961712 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s rankings:
Aerie Pharmaceuticals stock opened at $53.95 on Friday. The firm has a market capitalization of $2,178.03, a PE ratio of -16.01 and a beta of 0.95. Aerie Pharmaceuticals has a fifty-two week low of $38.14 and a fifty-two week high of $66.60. The company has a current ratio of 10.09, a quick ratio of 10.09 and a debt-to-equity ratio of 0.91.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($0.17). sell-side analysts anticipate that Aerie Pharmaceuticals will post -3.62 earnings per share for the current year.
Several equities research analysts have issued reports on the company. BidaskClub upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, January 22nd. Seaport Global Securities assumed coverage on Aerie Pharmaceuticals in a research report on Friday, January 26th. They set a “buy” rating and a $78.00 target price on the stock. Mizuho restated a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a research report on Monday, January 29th. Finally, Canaccord Genuity increased their target price on Aerie Pharmaceuticals from $73.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $78.75.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/20/aerie-pharmaceuticals-aeri-receives-media-impact-score-of-0-11.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.